A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
ApexOnco Front Page
Recent articles
With a slashed valuation the newly listed biotech heads for phase 3.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
New draft guidance could see the agency getting ever stricter.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
